TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $129.88.

Several brokerages have recently issued reports on TMDX. Oppenheimer upped their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research report on Tuesday, June 17th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Piper Sandler reissued an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider owned 13,955 shares of the company's stock, valued at approximately $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,418 shares of company stock worth $1,512,613 over the last three months. Corporate insiders own 7.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. NBC Securities Inc. purchased a new position in shares of TransMedics Group during the first quarter worth $25,000. Opal Wealth Advisors LLC purchased a new position in shares of TransMedics Group during the second quarter worth $26,000. Smartleaf Asset Management LLC raised its holdings in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after purchasing an additional 135 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of TransMedics Group during the fourth quarter worth $31,000. Finally, Quarry LP raised its holdings in shares of TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Price Performance

TMDX stock traded down $1.16 during mid-day trading on Friday, hitting $115.72. The company had a trading volume of 475,987 shares, compared to its average volume of 1,375,022. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of 85.06 and a beta of 2.06. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a quick ratio of 8.32, a current ratio of 9.10 and a debt-to-equity ratio of 1.92. The company has a 50-day moving average price of $125.98 and a 200 day moving average price of $91.24.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The business's quarterly revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.35 EPS. On average, research analysts anticipate that TransMedics Group will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.